<DOC>
	<DOCNO>NCT00304603</DOCNO>
	<brief_summary>The purpose study explore mode action topiramate treatment obese diabetic patient test association genetic variation within candidate gene chromosome ( thread like structure find cell carry gene ) clinical outcome .</brief_summary>
	<brief_title>Mode Action Topiramate Treatment Obese Patients With Without Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This pharmacogenomics ( effect genetic variation drug response ) study analyze genetic variation DNA extract blood sample collect patient randomize ( assigned treatment chance ) 1 3 previous topiramate study obesity diabetes . The study consist screen telephone contact , single visit study site blood sample collection ( 10 ml whole blood ) genetic analysis , 24-hour post-sample adverse event reporting period . The total duration study 24 hour time blood sample collection . Safety monitor 24 hour blood sample collection . No study medication administer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Must randomize within previous topiramate obesity diabetes study : PRI/TOPINT31 PRI/TOPINT33 subset patient diabetes mellitus randomize within PRI/TOPINT34 study site also participate PRI/TOPINT31 study Must consent participate use data previous clinical trial connection result genetic analysis Patients receive blood transfusion within 60 day collect DNA sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Pharmacogenomics</keyword>
	<keyword>DNA Polymorphism</keyword>
</DOC>